FMC-242

FMC-242 is a **covalent allosteric inhibitor** designed to disrupt the interaction between **phosphoinositide 3-kinase alpha (PI3Kα)** and **RAS proteins**, thereby **inhibiting downstream effector signaling in tumor cells**. Its primary indication is for use as a **precision oncology therapeutic** in cancers where PI3Kα and RAS play a critical role in tumorigenesis. By targeting the interface of these two proteins, FMC-242 aims to address previously undruggable cancer-driving mechanisms[1][3][9]. The molecule is under development by Frontier Medicines and is distinguished by its mechanism, which involves covalently and allosterically binding to the complex rather than traditional orthosteric inhibition.